Boston Life interim Parkinson trial positive
BOSTON, Jan 26 (Reuters) - Boston Life Sciences Inc. (Nasdaq:BLSI -
news) said
Tuesday that an interim analysis of the Phase II trial of Altropane, its
radioimaging
agent for the early diagnosis of Parkinson's Disease showed that
subjects with early
and/or mild Parkinson's Disease could be readily differentiated from
normal subjects based on an Altropane brain scan.
Boston Life noted that this trial was different from the company's
previously Phase II trial in which Parkinson subjects
had a more advanced disease.
According to the comapny, the subjects entered into the current trial
resembled quite closely the patient population that
potentially would be candidates for Altropane scanning if and when the
agent became commercially available.
--
Judith Richards, London, Ontario, Canada
<[log in to unmask]>
^^^
\ /
\ | / Today’s Research
\\ | // ...Tomorrow’s Cure
\ | /
\|/
```````
